Published in Cancer Weekly, November 5th, 2002
Barr said that it will file a court action in the U.S. District Court for the District of Columbia, seeking to reaffirm the April 1987 FDA final approval of its tamoxifen product, which established August 20, 2002, as the effective launch date for the company's product. If the FDA decision is upheld, it would delay the launch of Barr's manufactured tamoxifen 10-mg tablets until the expiration of pediatric exclusivity in February...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.